VarmX will use the combination of a €7.5m Series A financing co-led by BioGeneration Ventures (BGV) and Dutch regional development company InnovationQuarter plus an €5m innovation credit from the Netherlands Enterprise Agency (RVO.nl) to develop a modified blood coagulation factor X to prevent severe bleeding in haemophilia patients.
ADVERTISEMENT
The EMAs CHMP recommended nine medicines including six orphan medicines for EU market approval on Friday.